367 related articles for article (PubMed ID: 34683978)
1. Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan.
Burhan AM; Klahan B; Cummins W; Andrés-Guerrero V; Byrne ME; O'Reilly NJ; Chauhan A; Fitzhenry L; Hughes H
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683978
[TBL] [Abstract][Full Text] [Related]
2. Colloidal nanosystems with mucoadhesive properties designed for ocular topical delivery.
Silva B; São Braz B; Delgado E; Gonçalves L
Int J Pharm; 2021 Sep; 606():120873. PubMed ID: 34246741
[TBL] [Abstract][Full Text] [Related]
3. A review on recent drug delivery systems for posterior segment of eye.
Nayak K; Misra M
Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
[TBL] [Abstract][Full Text] [Related]
4. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
Qi Q; Wei Y; Zhang X; Guan J; Mao S
J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional carboxymethyl chitosan derivatives-layered double hydroxide hybrid nanocomposites for efficient drug delivery to the posterior segment of the eye.
Wang Y; Zhou L; Fang L; Cao F
Acta Biomater; 2020 Mar; 104():104-114. PubMed ID: 31931169
[TBL] [Abstract][Full Text] [Related]
6. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
[TBL] [Abstract][Full Text] [Related]
7. Mucoadhesive phenylboronic acid conjugated chitosan oligosaccharide-vitamin E copolymer for topical ocular delivery of voriconazole: Synthesis, in vitro/vivo evaluation, and mechanism.
Sun X; Sheng Y; Li K; Sai S; Feng J; Li Y; Zhang J; Han J; Tian B
Acta Biomater; 2022 Jan; 138():193-207. PubMed ID: 34757228
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems.
Wu KY; Joly-Chevrier M; Akbar D; Tran SD
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111579
[TBL] [Abstract][Full Text] [Related]
9. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.
Varela-Fernández R; Díaz-Tomé V; Luaces-Rodríguez A; Conde-Penedo A; García-Otero X; Luzardo-Álvarez A; Fernández-Ferreiro A; Otero-Espinar FJ
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32188045
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
[TBL] [Abstract][Full Text] [Related]
11. The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems.
Aceves-Franco LA; Sanchez-Aguilar OE; Barragan-Arias AR; Ponce-Gallegos MA; Navarro-Partida J; Santos A
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509540
[TBL] [Abstract][Full Text] [Related]
12. Can (Natural) deep eutectic systems increase the efficacy of ocular therapeutics?
Sarmento C; Duarte ARC; Rita Jesus A
Eur J Pharm Biopharm; 2024 May; 198():114276. PubMed ID: 38582179
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities for drug delivery to the posterior of the eye.
Cabrera FJ; Wang DC; Reddy K; Acharya G; Shin CS
Drug Discov Today; 2019 Aug; 24(8):1679-1684. PubMed ID: 31175955
[TBL] [Abstract][Full Text] [Related]
14. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.
Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD
Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378
[TBL] [Abstract][Full Text] [Related]
15. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
Wang R; Gao Y; Liu A; Zhai G
J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
[TBL] [Abstract][Full Text] [Related]
16. Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective.
Dave RS; Goostrey TC; Ziolkowska M; Czerny-Holownia S; Hoare T; Sheardown H
J Control Release; 2021 Aug; 336():71-88. PubMed ID: 34119558
[TBL] [Abstract][Full Text] [Related]
17. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
Alshaikh RA; Waeber C; Ryan KB
Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
[TBL] [Abstract][Full Text] [Related]
18. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology in retinal drug delivery.
Jiang S; Franco YL; Zhou Y; Chen J
Int J Ophthalmol; 2018; 11(6):1038-1044. PubMed ID: 29977820
[TBL] [Abstract][Full Text] [Related]
20. Chitosan/sulfobutylether-β-cyclodextrin based nanoparticles coated with thiolated hyaluronic acid for indomethacin ophthalmic delivery.
Ricci F; Racaniello GF; Lopedota A; Laquintana V; Arduino I; Lopalco A; Cutrignelli A; Franco M; Sigurdsson HH; Denora N
Int J Pharm; 2022 Jun; 622():121905. PubMed ID: 35697201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
